Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity

NCT07504172 | Not Yet Recruiting FDA Drug

• 1 other identifier: 202508
• Study Type: observational
• Target: 1,700
• Locations: 1 country
• Sites: 10

Brief Summary

Tirzepatide is one of the new medications for the treatment of obesity. In clinical research people treated with Tirzepatide have weight loss up to 21%. But there is only a little bit of research showing the effect of Tirzepatide in clinical practice. In this retrospective observational study the investigators will evaluate the effectiveness of tirzepatide in routine clinical practice among adults with obesity in the Netherlands.The main questions it aims to answer are:

• How much weight do patients lose after six months of treatment with tirzepatide combined with lifestyle coaching?
• How is the medication dosed in daily practice? Researchers will use data from electronic health records of patients in multiple outpatient locations of the Dutch Obesity Clinic (NOK, Nederlandse Obesitas Kliniek).

Conditions

Overweight , Obesity; Obesity (Disorder)

Keywords

Obesity; Weightloss; Tirzepatide; Adults; Body composition; Dose escalation

Outcome Measures

Primary Outcomes (1)

• Weight change

  %TWL= (start weight - 6 month weight/baseline weight)\*100%

  Baseline-6 months

Secondary Outcomes (6)

• Changes in body composition

  Basline-6 months

• Demographic and clinical characteristics

  Baseline

• Weight loss by maintenance dose

  Baseline-6 months

• Tirzepatide dosing patterns

  Baseline-6 months

• Weigth

  Baseline-6 months

Study Arms (1)

People with obesity

Adults

Drug: Tirzepatide

Interventions

Tirzepatide DRUG

Initiating treatment with tirzepatide

Also known as: Mounjaro

People with obesity

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Outpatient clinic

You may qualify if:

• Adults (age ≥18 years old)
• A BMI of ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 with at least one obesity complication (e.g., hypertension, dyslipidaemia)

You may not qualify if:

• Pregnant women or pregnancy during treatment
• Previously treated for obesity (with pharmacotherapy, endoscopic treatment or metabolic-bariatric surgery)
• Patients with diabetes

Sponsors & Collaborators

• Radboud University Medical Center: lead
• Nederlandse Obesitas Kliniek: collaborator

Study Sites (10)

NOK clinics

Amsterdam, Netherlands

Location

NOK clinics

Arnhem, Netherlands

Location

NOK clinics

Beverwijk, Netherlands

Location

NOK clinics

Gouda, Netherlands

Location

NOK clinics

Heerlen, Netherlands

Location

NOK clinics

Hoogeveen, Netherlands

Location

NOK clinics

Nieuwegein, Netherlands

Location

NOK clinics

Terneuzen, Netherlands

Location

NOK clinics

The Hague, Netherlands

Location

NOK clinics

Venlo, Netherlands

Location

Related Publications (3)

• McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Fruhbeck G, Goossens GH, Monami M, Sbraccia P, Martinez-Tellez B, Woodward E, Yumuk V. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025 Oct;31(10):3317-3329. doi: 10.1038/s41591-025-03978-z. Epub 2025 Oct 2.

  PMID: 41039116 BACKGROUND

• Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I; SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025 Mar 6;392(10):958-971. doi: 10.1056/NEJMoa2410819. Epub 2024 Nov 13.

  PMID: 39536238 BACKGROUND

• Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.

  PMID: 35658024 BACKGROUND

MeSH Terms

Conditions

Overweight; Obesity; Weight Loss

Interventions

Tirzepatide

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Body Weight Changes

Intervention Hierarchy (Ancestors)

Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide Receptors; Receptors, G-Protein-Coupled; Receptors, Cell Surface; Membrane Proteins; Proteins; Amino Acids, Peptides, and Proteins; Receptors, Gastrointestinal Hormone; Receptors, Peptide

Study Officials

• Maria Hopman, MD, PhD

  Radboud University Medical Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Puck van den Hooff, MD

CONTACT

+31649653657; puck.vandenhooff@radboudumc.nl

Valerie Monpellier, MD, PhD

CONTACT

+31645247665; vmonpellier@obesitaskliniek.nl

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 20, 2026
• First Posted: March 31, 2026
• Study Start: April 1, 2026
• Primary Completion: July 1, 2026
• Study Completion: August 1, 2026
• Last Updated: March 31, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

NL (10)